Covered recipient · General Payments record
ELIAS J JABBOUR
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2019 · Entire year
$120,282.65
108 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2019 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $46,790.00 | 13 |
| Travel and Lodging | $39,394.59 | 31 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $23,110.00 | 22 |
| Compensation for serving as faculty or as a speaker for an accredited or certified continuing education program | $8,500.00 | 1 |
| Food and Beverage | $2,488.06 | 41 |
By paying entity
PY2019 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Amgen Inc. | $27,122.42 | 20 |
| PFIZER INC. | $25,806.78 | 28 |
| Hikma Pharmaceuticals USA | $19,029.00 | 5 |
| Incyte Corporation | $12,828.41 | 7 |
| Kite Pharma, Inc. | $10,447.22 | 9 |
| E.R. Squibb & Sons, L.L.C. | $9,239.42 | 20 |
| Daiichi Sankyo Inc. | $4,793.77 | 6 |
| Novartis Pharmaceuticals Corporation | $4,125.00 | 1 |
| AbbVie, Inc. | $3,250.00 | 1 |
| Adaptive Biotechnologies Corporation | $3,229.94 | 3 |
| Genentech USA, Inc. | $211.42 | 4 |
| Astellas Pharma US Inc | $174.31 | 2 |
| Merck Sharp & Dohme Corporation | $13.26 | 1 |
| GlaxoSmithKline, LLC. | $11.70 | 1 |
Page 3 of 3; records 101–108 of 108 matching records. This page contains 8 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
ELIAS J JABBOUR
NPI 1215108303 · CMS profile ID 145451
Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
HOUSTON, TX
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 3; records 101–108 of 108 matching records. This page contains 8 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1215108303?year=2019&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- ELIAS J JABBOUR, NPI 1215108303, CMS profile ID 145451. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–108 of 108 matching records. This page contains 8 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1215108303?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- APA 7
- IndustryPayments. (2026). ELIAS J JABBOUR, NPI 1215108303, CMS profile ID 145451. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–108 of 108 matching records. This page contains 8 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1215108303?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- Bluebook
- ELIAS J JABBOUR, NPI 1215108303, CMS profile ID 145451, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–108 of 108 matching records. This page contains 8 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1215108303?year=2019&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30
108 matching records · $120,282.65 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–108 of 108.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $372.78 | 02/05/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 651290033 | CMS |
| E.R. Squibb & Sons, L.L.C. | $88.44 | 02/05/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 651290035 | CMS |
| E.R. Squibb & Sons, L.L.C. | $159.88 | 02/05/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 651290053 | CMS |
| E.R. Squibb & Sons, L.L.C. | $55.00 | 02/05/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 651290055 | CMS |
| E.R. Squibb & Sons, L.L.C. | $111.07 | 01/23/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 651289969 | CMS |
| PFIZER INC. | $780.00 | 01/18/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673795623 | CMS |
| PFIZER INC. | $780.00 | 01/14/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673794857 | CMS |
| PFIZER INC. | $3,200.00 | 01/02/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673795297 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $4,006.59 | 7 |
| PY2025 | Principal investigator | $73,248,563.28 | 50 |
| PY2024 | Recipient | $9,386.00 | 3 |
| PY2024 | Principal investigator | $35,345,738.74 | 69 |
| PY2023 | Recipient | $6,000.00 | 3 |
| PY2023 | Principal investigator | $34,282,742.92 | 57 |
| PY2022 | Recipient | $330.00 | 1 |
| PY2022 | Principal investigator | $41,750,052.06 | 64 |
| PY2021 | Recipient | $1,524.53 | 3 |
| PY2021 | Principal investigator | $38,675,338.28 | 51 |
| PY2020 | Recipient | $21,090.58 | 7 |
| PY2020 | Principal investigator | $23,293,883.37 | 60 |
| PY2019 | Recipient | $149.67 | 1 |
| PY2019 | Principal investigator | $16,200,987.04 | 39 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
57 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $208,546.66 | 12/16/2025 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | PONATINIB AS SECOND LINE THERAPY FOR PATIENTS WITH CML IN CHRONIC PHASE RESISTANT OR INTOLERANT TO IMATINIB, DASATINIB OR NILOTINIB | No dispute reported | 06/30/2026 | 1223273051 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $434,274.00 | 12/09/2025 | Non-covered Recipient Entity THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER | Open/label phase II study of asciminib as second line therapy for adult patients with CML/CP post frontline TKI failure | No dispute reported | 06/30/2026 | 1190309304 |
| Recipient | Novartis Pharmaceuticals Corporation | $786.00 | 12/08/2025 | Covered Recipient Physician | Research Publication/ Writing Support | No dispute reported | 06/30/2026 | 1190291481 |
| Principal investigator 1 | PFIZER INC. | $458,160.00 | 12/08/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | TREATMENT OF RELAPSED OR REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA ALL WITH CMC544 INOTUZUMAB OZOGAMYCIN WITH OR WITHOUT LATER ADDITION OF RITUXIMAB | No dispute reported | 06/30/2026 | 1228740011 |
| Principal investigator 1 | PFIZER INC. | $458,160.00 | 12/08/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | PHASE II STUDY OF THE HYPERCVAD REGIMEN IN SEQUENTIAL COMBINATION WITH BLINATUMOMAB AND INOTUZUMAB OZOGAMICIN AS FRONTLINE THERAPY FOR ADULTS WITH BCELL LINEAGE ACUTE LYMPHOCYTIC LEUKEMIA | No dispute reported | 06/30/2026 | 1228747230 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $1,628,527.50 | 12/01/2025 | Non-covered Recipient Entity THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER | Phase II Study assessing safety and clinical activity of asciminib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) | No dispute reported | 06/30/2026 | 1190309302 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,869.90 | 11/25/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A First in Human Study of the MeninKMT2A MLL1 Inhibitor JNJ75276617 in Participants with Acute Leukemia | No dispute reported | 06/30/2026 | 1175402972 |
| Principal investigator 1 | Janssen Research & Development, LLC | $832.00 | 10/30/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 1b Study of JNJ-75276617 in Combination with AML Directed Therapies for Participants with Acute Myeloid Leukemia Harboring KMT2A or NPM1 Alterations | No dispute reported | 06/30/2026 | 1175403292 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $5,830,000.00 | 10/21/2025 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | PHASE II STUDY OF THE COMBINATION OF BLINATUMOMAB AND PONATINIB IN PATIENTS WITH PHILADELPHIA CHROMOSOME (PH)-POSITIVE AND/OR BCR-ABL POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) | No dispute reported | 06/30/2026 | 1223273041 |
| Principal investigator 1 | Janssen Research & Development, LLC | $72,470.00 | 10/13/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 3 Randomized, Double-blind, Placebo-controlled, Study of Bleximenib, Venetoclax and Azacitidine for the Treatment of Participants with Newly Diagnosed Acute Myeloid Leukemia Harboring KMT2ARearrangements or NPM1Mutations who are Ineligible for Intensive Chemotherapy | No dispute reported | 06/30/2026 | 1175403024 |
| Principal investigator 1 | Amgen Inc. | $69.37 | 10/08/2025 | Non-covered Recipient Entity MD ANDERSON CANCER CENTER | A Phase 1/2 Open-label Study to Investigate the Safety, Efficacy, and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL) and Minimal Residual Disease Positive (MRD+) B-ALL | No dispute reported | 06/30/2026 | 1246644041 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,869.90 | 10/03/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A First in Human Study of the MeninKMT2A MLL1 Inhibitor JNJ75276617 in Participants with Acute Leukemia | No dispute reported | 06/30/2026 | 1175403663 |
| Principal investigator 1 | Adaptive Biotechnologies Corporation | $4,950.00 | 10/02/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | 2010-0991 | No dispute reported | 06/30/2026 | 1254908893 |
| Principal investigator 1 | PFIZER INC. | $458,160.00 | 09/17/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | TREATMENT OF RELAPSED OR REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA ALL WITH CMC544 INOTUZUMAB OZOGAMYCIN WITH OR WITHOUT LATER ADDITION OF RITUXIMAB | No dispute reported | 06/30/2026 | 1228747915 |
| Principal investigator 1 | Amgen Inc. | $1,834,203.60 | 09/16/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | Phase I/II Study of the Combination of Inotuzumab Ozogamycin (CMC-544) with Low-intensity Chemotherapy in Patients with Acute Lymphoblastic Leukemia (ALL) | No dispute reported | 06/30/2026 | 1246638190 |
| Principal investigator 1 | ABBVIE INC. | $2,081.60 | 09/03/2025 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | PHASE I/II STUDY OF THE COMBINATION OF LOW-INTENSITY CHEMOTHERAPY AND VENETOCLAX (ABT-199) IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) | No dispute reported | 06/30/2026 | 1202431641 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,212,640.00 | 08/28/2025 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | PHASE II STUDY OF COMBINATION OF HYPER-CVAD AND PONATINIB IN PATIENTS WITH PHILADELPHIA (PH) CHROMOSOME POSITIVE AND/OR BCR-ABL POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) | No dispute reported | 06/30/2026 | 1223273031 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,869.90 | 08/07/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A First in Human Study of the MeninKMT2A MLL1 Inhibitor JNJ75276617 in Participants with Acute Leukemia | No dispute reported | 06/30/2026 | 1175403486 |
| Recipient | Novartis Pharmaceuticals Corporation | $324.09 | 08/05/2025 | Covered Recipient Physician | Research Publication/ Writing Support | No dispute reported | 06/30/2026 | 1190293501 |
| Principal investigator 1 | Autolus Inc | $4,938.00 | 07/31/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | AUTO1-AL1 | No dispute reported | 06/30/2026 | 1243667764 |
| Principal investigator 1 | Autolus Inc | $3,750.00 | 07/31/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | AUTO1-AL1 | No dispute reported | 06/30/2026 | 1243667766 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $5,363,600.00 | 07/24/2025 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | PHASE II STUDY OF THE COMBINATION OF BLINATUMOMAB AND PONATINIB IN PATIENTS WITH PHILADELPHIA CHROMOSOME (PH)-POSITIVE AND/OR BCR-ABL POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) | No dispute reported | 06/30/2026 | 1223273013 |
| Principal investigator 1 | PFIZER INC. | $939,228.00 | 07/09/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | TREATMENT OF RELAPSED OR REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA ALL WITH CMC544 INOTUZUMAB OZOGAMYCIN WITH OR WITHOUT LATER ADDITION OF RITUXIMAB | No dispute reported | 06/30/2026 | 1228740105 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,332,000.00 | 07/02/2025 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | CCR-MDACC-PON-002: PHASE II STUDY OF THE SEQUENTIAL COMBINATION OF LOW-INTENSITY CHEMOTHERAPY AND PONATINIB FOLLOWED BY BLINATUMOMAB AND PONATINIB IN PATIENTS WITH PHILADELPHIA CHROMOSOME (PH)-POSITIVE AND/OR BCR-ABL POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) | No dispute reported | 06/30/2026 | 1223273009 |
| Principal investigator 1 | PFIZER INC. | $687,240.00 | 06/23/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | PHASE II STUDY OF THE HYPERCVAD REGIMEN IN SEQUENTIAL COMBINATION WITH BLINATUMOMAB AND INOTUZUMAB OZOGAMICIN AS FRONTLINE THERAPY FOR ADULTS WITH BCELL LINEAGE ACUTE LYMPHOCYTIC LEUKEMIA | No dispute reported | 06/30/2026 | 1228754475 |
| Recipient | PFIZER INC. | $940.00 | 06/15/2025 | Covered Recipient Physician | BOSUTINIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228770292 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,869.90 | 06/04/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A First in Human Study of the MeninKMT2A MLL1 Inhibitor JNJ75276617 in Participants with Acute Leukemia | No dispute reported | 06/30/2026 | 1175403124 |
| Recipient | PFIZER INC. | $940.00 | 06/01/2025 | Covered Recipient Physician | BOSUTINIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228760985 |
| Principal investigator 1 | PFIZER INC. | $343,620.00 | 05/21/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | TREATMENT OF RELAPSED OR REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA ALL WITH CMC544 INOTUZUMAB OZOGAMYCIN WITH OR WITHOUT LATER ADDITION OF RITUXIMAB | No dispute reported | 06/30/2026 | 1228751865 |
| Recipient | Novartis Pharmaceuticals Corporation | $356.50 | 05/15/2025 | Covered Recipient Physician | Research Publication/Writing Support | No dispute reported | 06/30/2026 | 1190293505 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $511,050.00 | 05/12/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | Phase II Study assessing safety and clinical activity of asciminib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) | No dispute reported | 06/30/2026 | 1190294280 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,739.80 | 05/05/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A First in Human Study of the MeninKMT2A MLL1 Inhibitor JNJ75276617 in Participants with Acute Leukemia | No dispute reported | 06/30/2026 | 1175402940 |
| Principal investigator 1 | Janssen Research & Development, LLC | $47,514.00 | 05/05/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 1b Study of JNJ-75276617 in Combination with AML Directed Therapies for Participants with Acute Myeloid Leukemia Harboring KMT2A or NPM1 Alterations | No dispute reported | 06/30/2026 | 1175403727 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,490,400.00 | 04/28/2025 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | PONATINIB AS SECOND LINE THERAPY FOR PATIENTS WITH CML IN CHRONIC PHASE RESISTANT OR INTOLERANT TO IMATINIB, DASATINIB OR NILOTINIB | No dispute reported | 06/30/2026 | 1223272989 |
| Principal investigator 1 | Amgen Inc. | $6,863,792.80 | 04/16/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | Phase II Study of the Hyper-CVAD Regimen in Sequential Combination with Blinatumomab with or without Inotuzumab Ozogamicin as Frontline Therapy for Adults with B-Cell Lineage Acute Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1246638194 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,418,640.00 | 04/10/2025 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | PHASE II STUDY OF THE COMBINATION OF BLINATUMOMAB AND PONATINIB IN PATIENTS WITH PHILADELPHIA CHROMOSOME (PH)-POSITIVE AND/OR BCR-ABL POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) | No dispute reported | 06/30/2026 | 1223272985 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,109,360.00 | 04/10/2025 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | PHASE II STUDY OF THE COMBINATION OF BLINATUMOMAB AND PONATINIB IN PATIENTS WITH PHILADELPHIA CHROMOSOME (PH)-POSITIVE AND/OR BCR-ABL POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) | No dispute reported | 06/30/2026 | 1223272987 |
| Principal investigator 1 | PFIZER INC. | $366,528.00 | 04/07/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | PHASE II STUDY OF THE HYPERCVAD REGIMEN IN SEQUENTIAL COMBINATION WITH BLINATUMOMAB AND INOTUZUMAB OZOGAMICIN AS FRONTLINE THERAPY FOR ADULTS WITH BCELL LINEAGE ACUTE LYMPHOCYTIC LEUKEMIA | No dispute reported | 06/30/2026 | 1228753784 |
| Principal investigator 1 | Amgen Inc. | $3,668,932.80 | 04/04/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | Phase II Study of the Combination of Blinatumomab and Ponatinib in Patients with Philadelphia Chromosome (Ph)-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL) | No dispute reported | 06/30/2026 | 1246638192 |
| Principal investigator 1 | Janssen Research & Development, LLC | $12,694.00 | 04/03/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 1b Study of JNJ-75276617 in Combination with AML Directed Therapies for Participants with Acute Myeloid Leukemia Harboring KMT2A or NPM1 Alterations | No dispute reported | 06/30/2026 | 1175403419 |
| Principal investigator 1 | Amgen Inc. | $2,500.00 | 03/25/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | Phase 3 Randomized, Controlled Study of Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia With Safety Run-in (Golden Gate Study) | No dispute reported | 06/30/2026 | 1246638188 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,869.90 | 03/10/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A First in Human Study of the MeninKMT2A MLL1 Inhibitor JNJ75276617 in Participants with Acute Leukemia | No dispute reported | 06/30/2026 | 1175402873 |
| Principal investigator 1 | ABBVIE INC. | $166,095.28 | 03/03/2025 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | PHASE I/II STUDY OF THE COMBINATION OF LOW-INTENSITY CHEMOTHERAPY AND VENETOCLAX (ABT-199) IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA | No dispute reported | 06/30/2026 | 1202430226 |
| Principal investigator 1 | Janssen Research & Development, LLC | $9,641.00 | 03/03/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 1b Study of JNJ-75276617 in Combination with AML Directed Therapies for Participants with Acute Myeloid Leukemia Harboring KMT2A or NPM1 Alterations | No dispute reported | 06/30/2026 | 1175403712 |
| Recipient | PFIZER INC. | $330.00 | 02/28/2025 | Covered Recipient Physician | BOSUTINIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228768482 |
| Recipient | PFIZER INC. | $330.00 | 02/28/2025 | Covered Recipient Physician | BOSUTINIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228768539 |
| Principal investigator 1 | ABBVIE INC. | $12,780.40 | 02/27/2025 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | PHASE I/II STUDY OF THE COMBINATION OF LOW-INTENSITY CHEMOTHERAPY AND VENETOCLAX (ABT-199) IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA | No dispute reported | 06/30/2026 | 1202430076 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $3,582,760.50 | 02/10/2025 | Non-covered Recipient Entity MD ANDERSON CANCER CENTER UNIVERSITY OF TEXAS | Open/label phase II study of asciminib as second line therapy for adult patients with CML/CP post frontline TKI failure | No dispute reported | 06/30/2026 | 1190306657 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,584,800.00 | 02/06/2025 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | PHASE II STUDY OF COMBINATION OF HYPER-CVAD AND PONATINIB IN PATIENTS WITH PHILADELPHIA (PH) CHROMOSOME POSITIVE AND/OR BCR-ABL POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) | No dispute reported | 06/30/2026 | 1223272965 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,811,200.00 | 01/30/2025 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | PONATINIB AS SECOND LINE THERAPY FOR PATIENTS WITH CML IN CHRONIC PHASE RESISTANT OR INTOLERANT TO IMATINIB, DASATINIB OR NILOTINIB | No dispute reported | 06/30/2026 | 1223272961 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,811,200.00 | 01/30/2025 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | PONATINIB AS SECOND LINE THERAPY FOR PATIENTS WITH CML IN CHRONIC PHASE RESISTANT OR INTOLERANT TO IMATINIB, DASATINIB OR NILOTINIB | No dispute reported | 06/30/2026 | 1223272963 |
| Principal investigator 1 | ABBVIE INC. | $398,259.00 | 01/28/2025 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A16-219;Venclexta;Bottle: ABT-263 100mg Film Coated Tablet 60 Tablets | No dispute reported | 06/30/2026 | 1202429845 |
| Principal investigator 1 | PFIZER INC. | $343,620.00 | 01/13/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | PHASE II STUDY OF THE HYPERCVAD REGIMEN IN SEQUENTIAL COMBINATION WITH BLINATUMOMAB AND INOTUZUMAB OZOGAMICIN AS FRONTLINE THERAPY FOR ADULTS WITH BCELL LINEAGE ACUTE LYMPHOCYTIC LEUKEMIA | No dispute reported | 06/30/2026 | 1228751537 |
| Principal investigator 1 | Amgen Inc. | $5,783,014.97 | 01/09/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 1/2 Open-label Study to Investigate the Safety, Efficacy, and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL) and Minimal Residual Disease Positive (MRD+) B-ALL | No dispute reported | 06/30/2026 | 1246638142 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $4,528,000.00 | 01/09/2025 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | PHASE II STUDY OF THE COMBINATION OF BLINATUMOMAB AND PONATINIB IN PATIENTS WITH PHILADELPHIA CHROMOSOME (PH)-POSITIVE AND/OR BCR-ABL POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) | No dispute reported | 06/30/2026 | 1223272955 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $12,268,240.50 | 01/06/2025 | Non-covered Recipient Entity MD ANDERSON CANCER CENTER UNIVERSITY OF TEXAS | Phase II Study assessing safety and clinical activity of asciminib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) | No dispute reported | 06/30/2026 | 1190306655 |
| Principal investigator 1 | PFIZER INC. | $160,000.00 | 01/06/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | PHASE II STUDY OF THE HYPERCVAD REGIMEN IN SEQUENTIAL COMBINATION WITH BLINATUMOMAB AND INOTUZUMAB OZOGAMICIN AS FRONTLINE THERAPY FOR ADULTS WITH BCELL LINEAGE ACUTE LYMPHOCYTIC LEUKEMIA | No dispute reported | 06/30/2026 | 1228800960 |